These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 30375710)
1. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence. Teegen EM; Dürr M; Maurer MM; Eurich F; Vollbort A; Globke B; Bahra M; Blaeker H; Pratschke J; Eurich D Transpl Infect Dis; 2019 Feb; 21(1):e13020. PubMed ID: 30375710 [TBL] [Abstract][Full Text] [Related]
2. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610 [TBL] [Abstract][Full Text] [Related]
3. Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study. Faisal N; Bilodeau M; Aljudaibi B; Hirch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Lilly LB Exp Clin Transplant; 2019 Feb; 17(1):59-63. PubMed ID: 29619910 [TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin. Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544 [TBL] [Abstract][Full Text] [Related]
5. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens. Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446 [TBL] [Abstract][Full Text] [Related]
6. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Martini S; Sacco M; Strona S; Arese D; Tandoi F; Dell Olio D; Stradella D; Cocchis D; Mirabella S; Rizza G; Magistroni P; Moschini P; Ottobrelli A; Amoroso A; Rizzetto M; Salizzoni M; Saracco GM; Romagnoli R Liver Int; 2017 Jan; 37(1):62-70. PubMed ID: 27344058 [TBL] [Abstract][Full Text] [Related]
7. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629 [TBL] [Abstract][Full Text] [Related]
8. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C. Raschzok N; Schott E; Reutzel-Selke A; Damrah I; Gül-Klein S; Strücker B; Sauer IM; Pratschke J; Eurich D; Stockmann M Transpl Infect Dis; 2016 Dec; 18(6):896-903. PubMed ID: 27632190 [TBL] [Abstract][Full Text] [Related]
9. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population. Teegen EM; Globke B; Schott E; Pratschke J; Eurich D Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590 [TBL] [Abstract][Full Text] [Related]
10. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience. Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038 [TBL] [Abstract][Full Text] [Related]
11. Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD. Sise ME; Backman E; Ortiz GA; Hundemer GL; Ufere NN; Chute DF; Brancale J; Xu D; Wisocky J; Lin MV; Kim AY; Thadhani R; Chung RT Clin J Am Soc Nephrol; 2017 Oct; 12(10):1615-1623. PubMed ID: 28882857 [TBL] [Abstract][Full Text] [Related]
12. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients. Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. Shin HP; Park JA; Burman B; Kozarek RA; Siddique A Clin Mol Hepatol; 2017 Dec; 23(4):316-322. PubMed ID: 28827512 [TBL] [Abstract][Full Text] [Related]
15. Achieving Sustained Virological Response in Liver Transplant Recipients With Hepatitis C Decreases Risk of Decline in Renal Function. Satapathy SK; Joglekar K; Molnar MZ; Ali B; Gonzalez HC; Vanatta JM; Eason JD; Nair SP Liver Transpl; 2018 Aug; 24(8):1040-1049. PubMed ID: 29573131 [TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients. Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001 [TBL] [Abstract][Full Text] [Related]
17. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S; Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034 [TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. Dumortier J; Leroy V; Duvoux C; de Ledinghen V; Francoz C; Houssel-Debry P; Radenne S; d'Alteroche L; Fougerou-Leurent C; Canva V; di Martino V; Conti F; Kamar N; Moreno C; Lebray P; Tran A; Besch C; Diallo A; Rohel A; Rossignol E; Abergel A; Botta-Fridlund D; Coilly A; Samuel D; Duclos-Vallée JC; Pageaux GP Liver Transpl; 2016 Oct; 22(10):1367-78. PubMed ID: 27348086 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Sanchez Antolin G; Testillano M; Pascasio JM; Narvaez Rodriguez I; Prieto M; Otero A; Herrero JI; Londoño M; Fernandez Vazquez I; Castells L; Transplant Proc; 2016 Nov; 48(9):3013-3016. PubMed ID: 27932134 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]